An Open-Label Extension of BPS-MR-PAH-201 in Pulmonary Arterial Hypertension (PAH) Patients

ClinicalTrials.gov ID: NCT00792571

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT00792571. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Nov 13, 2026, 7:17 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

An Open-Label Extension of BPS-MR-PAH-201 in Pulmonary Arterial Hypertension (PAH) Patients.

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This is an open-label extension study for patients who participated in the BPS-MR-PAH-201 study.

Study identification

NCT ID: NCT00792571
Recruitment status: Completed
Study type: Interventional
Phase: Phase 2
Lead sponsor: Lung Biotechnology PBC; Industry
Enrollment: 18 participants

Conditions and interventions

Conditions

Pulmonary Arterial Hypertension

Interventions

Beraprost Sodium Modified Release Drug

Drug

Eligibility (public fields only)

Age range: 18 Years to 75 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Feb 28, 2009 (Actual)
Primary completion: Nov 30, 2013 (Actual)
Completion: Nov 30, 2013 (Actual)
Last update posted: Dec 26, 2019

2009 – 2013

United States locations

U.S. sites: 3
U.S. states: 3
U.S. cities: 3

Facility	City	State	ZIP	Site status
Harbor-UCLA Medical Center	Torrance	California	90502	—
Allegheny General Hospital	Pittsburgh	Pennsylvania	15212	—
UTSW Medical Center Dallas	Dallas	Texas	75390-8550	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 3 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT00792571, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Dec 26, 2019 · Synced Nov 13, 2026